Menarini
| Company type | Limited liability company |
|---|---|
| Industry | Pharmaceutical Health care and diagnostics |
| Founded | 1886 in Naples |
| Founder | Archimede Menarini |
| Headquarters | , Italy |
Area served | Worldwide |
Key people |
|
| Revenue | € 3,8 billion |
Number of employees | 17,650 (2020) |
| Subsidiaries | Arax Co., Ltd. (Japan) |
| Website | https://www.menarini.com/ |
The Menarini Group is an Italian pharmaceutical company. Its headquarters is in Florence, Tuscany, and it has three divisions: Menarini Ricerche, Menarini Biotech, and Menarini Diagnostics. It develops pharmacological solutions for cardiovascular diseases, oncology, pain/inflammation, asthma and anti-infectives. Menarini's research activities are carried out through Menarini Ricerche, which deals with all R&D activities, from the creation of new projects to drug registration. Its Menarini Biotech follows the creation of a biotechnological drug from the very early stages of research, through to the pilot scale and up to industrial production. The Group's Menarini Diagnostics division is a healthcare company with a worldwide network of affiliates partners and distributors focused on diabetes, haematology, clinical chemistry, urinalysis, and immunology. In 2020, the company had 17,650 employees worldwide.
Massimiliana Landini Aleotti and her three children inherited the company, valued at US$11.6 billion, following the death of her husband in May 2014.
Menarini developed a rapid COVID-19 test amid the COVID-19 pandemic in Italy, capable of giving a result in just 20 minutes.